Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02678793 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)
A Phase 2 study, sponsored by Centrexion Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT02678793 is a Phase 2 study that has completed, run by Centrexion Therapeutics. The registered enrollment target is 67 participants.
The verdict
NCT02678793, a Phase 2 study, has completed, sponsored by Centrexion Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
Subjects who have completed study 4975-MN-202 will be eligible to receive open-label treatment with CNTX-4975 200 µg in study 4975-MN-203 if they meet the inclusion/exclusion criteria.
Interventions
- DRUG CNTX-4975
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2015-12 |
| Est. Completion | 2017-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02678793
The ClinicalTrials.gov registry entry for NCT02678793 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centrexion Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CNTX-4975 is the first listed.
NCT02678793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02678793 about?
NCT02678793 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)". Subjects who have completed study 4975-MN-202 will be eligible to receive open-label treatment with CNTX-4975 200 µg in study 4975-MN-203 if they meet the inclusion/exclusion criteria.
What is the current status of trial NCT02678793?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2015-12. Estimated completion is 2017-03.
What interventions are being tested in trial NCT02678793?
The interventions under investigation include: CNTX-4975 (DRUG).
Who is sponsoring clinical trial NCT02678793?
This trial is sponsored by Centrexion Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.